You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1529 Results
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Jul 2021
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2021
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Oct 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Nov 2021
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer

Pages